Completed Private Placement

Serodus ASA has completed a private placement of 10 million shares directed towards selected leading Norwegian institutions and private investors. The subscription price was set at NOK 3,- per share, resulting in gross proceeds of NOK 30 million.

First patient enrolled in SER100 clinical study

The clinical phase IIa study of SER100 in patients with isolated systolic hypertension has been initiated. The first patient has been enrolled in the study, and the company plans to enroll a total of thirty patients over the next few months. Thus, the clinical study is on schedule and Serodus expects to report the results in the second quarter of 2014.

SER100 Patent found allowable in Canada

The Canadian Intellectual Property Office has issued a notice of allowance for the company's patent application "Peptide conjugates modified N- and/or C-terminally by short charged peptide chains".

Consequently, the company's lead compound SER100 is or will be covered by patents in Australia, New Zealand, Japan, Europe, the USA and Canada.

Serodus announces completed IPO

Serodus has raised NOK 4.050.000 in gross proceeds through an offering of 1.500.000 new shares at a subscription price of NOK 2.7 per share at a par value of NOK 1.3 per share. Read more...

Serodus launches Initial Public Offering

The board of directors of Serodus ASA ("Serodus" or the "Company") has today resolved to offer between 4,000 and 1,500,000 New Shares with the aim of raising gross proceeds of up to NOK 4,500,000 in the Initial Public Offering (the "Offering") to be completed in connection with the listing of the Company's shares on Oslo Axess. Read more...

Approved Prospectus

The Financial Supervisory Authority of Norway has approved the prospectus dated 7 March 2013 in connection with the initial public offering and the listing of Serodus ASA on Oslo Axess.The prospectus will be available here and at www.norne.no and will also be available free of charge at the business offices of Serodus ASA and Norne Securities AS. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Notice of ordinary general meeting 27 February 2013

The ordinary general meeting of Serodus ASA will be held on Wednesday 27 February at 10:00 in Oslo Research Park, Gaustadalléen 21, 0349 Oslo. For more information, please visit our Investor Relations page.